benralizumab   Click here for help

GtoPdb Ligand ID: 7674

Synonyms: BIW-8405 | Fasenra® | KHK4563 | MEDI-563
Approved drug Immunopharmacology Ligand
benralizumab is an approved drug (FDA (2017), EMA (2018))
Compound class: Antibody
Comment: Benralizumab is a humanized, afucosylated mAb targeting the IL5Rα which is expressed by cells of the eosinophil lineage. The antibody is afucosylated (ie has fucose containing oligosaccharide side-chains removed) to improve structure, stability, and biological function.
Peptide sequence information for this antibody is available from its IMGT/mAb-DB link.
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: benralizumab

1. Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, Gossage DL, Ward CK, Wu Y, Wang B et al.. (2014)
Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
Lancet Respir Med, 2 (11): 879-90. [PMID:25306557]
FDA Approves Fasenra.
Accessed on 16/11/2017. Modified on 16/11/2017.,
3. European Medicines Agency. 
Accessed on 16/11/2017. Modified on 16/11/2017.,
4. FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S et al.. (2016)
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet, 388 (10056): 2128-2141. [PMID:27609406]
5. Ghazi A, Trikha A, Calhoun WJ. (2012)
Benralizumab--a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma.
Expert Opin Biol Ther, 12 (1): 113-8. [PMID:22136436]
6. Koike M, Spitalny GL, Wheeler A, White B. (2013)
Methods of reducing eosinophil levels.
Patent number: US8501176. Assignee: Medimmune, Llc, Biowa, Inc.. Priority date: 14/05/2007. Publication date: 06/08/2013.
7. Mukherjee M, Sehmi R, Nair P. (2014)
Anti-IL5 therapy for asthma and beyond.
World Allergy Organ J, 7 (1): 32. [PMID:25709744]